Former Bristol Myers Squibb Company senior director for worldwide pricing strategy for cardiovascular immunology and fibrosis treatments Daniel Heider has joined the Centers for Medicare and Medicaid Services as director of the Division of Rebate Agreements and Drug Price Negotiations to help lead implementation of the new programs.
CMS Medicare Price Negotiation Division Headed By Former Bristol Myers Squibb Exec Heider
Most of the other leaders in the new organization within the Centers for Medicare and Medicaid Services tasked with implementing the price negotiation and inflation rebate programs previously worked in other parts of the agency, including the Center for Medicare and Medicaid Innovation.
More from Market Access
• By
Trump announced a 26% reciprocal tariff on India, but a country-agnostic exemption of pharmaceuticals implies that the interests of Indian firms are protected for now. What is Indian pharma’s business exposure and what is domestic industry saying?
• By
As CMS administrator, Mehmet Oz will oversee the second cycle of Medicare drug price negotiations and Part D redesign issues, but will have experienced deputies to help.
• By
Newly published insights from a series of European Medicines Agency workshops can guide drug developers in designing development plans that meet the needs of both regulators and health technology assessment bodies.
• By
England’s health technology assessment institute, NICE, is looking to “reimagine” its evaluation process with the help of AI, rather than just using this technology to speed up its existing processes.
More from Pink Sheet
• By
Newly published insights from a series of European Medicines Agency workshops can guide drug developers in designing development plans that meet the needs of both regulators and health technology assessment bodies.
• By
England’s health technology assessment institute, NICE, is looking to “reimagine” its evaluation process with the help of AI, rather than just using this technology to speed up its existing processes.
• By
Industry lobbing for pharmaceuticals to be exempt from President Trump’s sweeping US tariffs appears to have paid off.